Marinus Pharmaceuticals (NASDAQ:MRNS) Earns “Buy” Rating from Truist Financial

Truist Financial restated their buy rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNSFree Report) in a research note published on Tuesday morning, Benzinga reports. The firm currently has a $10.00 target price on the biopharmaceutical company’s stock.

Several other equities research analysts also recently issued reports on the company. Robert W. Baird reiterated a neutral rating on shares of Marinus Pharmaceuticals in a report on Tuesday, April 16th. Royal Bank of Canada reiterated a sector perform rating and issued a $3.00 target price (down previously from $24.00) on shares of Marinus Pharmaceuticals in a report on Monday, April 15th. Oppenheimer restated a market perform rating and set a $9.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, March 7th. Cantor Fitzgerald reaffirmed an overweight rating and issued a $28.00 price objective on shares of Marinus Pharmaceuticals in a research report on Wednesday, April 10th. Finally, StockNews.com cut shares of Marinus Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of Hold and an average price target of $13.79.

Get Our Latest Research Report on Marinus Pharmaceuticals

Marinus Pharmaceuticals Stock Down 3.2 %

Shares of NASDAQ MRNS opened at $1.35 on Tuesday. The company has a debt-to-equity ratio of 5.68, a current ratio of 3.07 and a quick ratio of 2.93. The company has a 50-day moving average price of $1.54 and a 200-day moving average price of $6.74. The stock has a market capitalization of $74.16 million, a P/E ratio of -0.51 and a beta of 1.11. Marinus Pharmaceuticals has a 1 year low of $1.11 and a 1 year high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNSGet Free Report) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.68). The business had revenue of $7.68 million during the quarter, compared to the consensus estimate of $8.61 million. Marinus Pharmaceuticals had a negative return on equity of 518.13% and a negative net margin of 513.80%. On average, equities research analysts forecast that Marinus Pharmaceuticals will post -1.87 EPS for the current fiscal year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Sherbrooke Park Advisers LLC purchased a new stake in Marinus Pharmaceuticals in the third quarter worth $141,000. Schonfeld Strategic Advisors LLC raised its stake in Marinus Pharmaceuticals by 69.5% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 253,412 shares of the biopharmaceutical company’s stock valued at $2,040,000 after acquiring an additional 103,935 shares during the period. Eventide Asset Management LLC lifted its holdings in Marinus Pharmaceuticals by 42.8% during the third quarter. Eventide Asset Management LLC now owns 4,529,997 shares of the biopharmaceutical company’s stock valued at $36,466,000 after purchasing an additional 1,356,800 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in Marinus Pharmaceuticals by 6.3% during the third quarter. Adage Capital Partners GP L.L.C. now owns 2,904,476 shares of the biopharmaceutical company’s stock worth $23,381,000 after purchasing an additional 173,226 shares during the period. Finally, Acuta Capital Partners LLC purchased a new position in shares of Marinus Pharmaceuticals in the third quarter worth about $157,000. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

(Get Free Report)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Featured Articles

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.